Related Experiment Video
Updated: May 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Acute management of ST-elevation myocardial infarction patients taking dabigatran
1Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada.
Insights
Novel oral anticoagulants are effective for nonvalvular atrial fibrillation but pose challenges during ST-elevation myocardial infarction. This case explores a pharmacoinvasive strategy for urgent percutaneous coronary intervention with dabigatran.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Novel oral anticoagulants (NOACs) are recommended for nonvalvular atrial fibrillation (NVAF).
- Warfarin therapy has limitations in managing NVAF.
- Contemporary guidelines endorse NOACs over warfarin.
Observation:
- Managing patients on NOACs presenting with ST-elevation myocardial infarction (STEMI) is challenging.
- Acute reperfusion therapy is critical for STEMI management.
- This case highlights the clinical dilemma of balancing anticoagulation with urgent intervention.
Findings:
- A logical, though not evidence-based, pharmacoinvasive strategy was applied.
- The strategy aimed to facilitate acute reperfusion therapy in a STEMI patient on dabigatran.
- Suggestions for urgent percutaneous coronary intervention (PCI) in patients taking dabigatran are proposed.
Implications:
- Clinicians face challenges managing STEMI patients on NOACs.
- The proposed strategy for urgent PCI with dabigatran requires cautious implementation.
- Further evidence is needed to refine management protocols for NOACs during acute coronary syndromes.
Abstract:
The novel oral anticoagulant agents provide compelling evidence-based advance over warfarin therapy in nonvalvular atrial fibrillation and have received endorsement from contemporary guidelines. This case illustrates the challenge that clinicians will have to manage patients taking these agents who present with ST-elevation myocardial infarction requiring acute reperfusion therapy. We used a "logical" although not evidence-based approach to applying a pharmacoinvasive strategy that might be considered by others. Additionally we propose suggestions for urgent percutaneous coronary intervention while taking dabigatran, a strategy that should be implemented cautiously and adapted as further evidence becomes available.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism III: Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
